Effects of fluoxetine on locomotor activity: Possible involvement of dopamine

Zhurnal Vysshei Nervnoi Deyatelnosti Imeni I.P. Pavlova

Volumn 56, Issue 4, 2006, Pages 523-528

  Shishkina, G T ^a   Yudina, A M ^a   Dygalo, N N ^a  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

Author keywords

5 hydroxyindoleacetic acid; Anxiety; Dopamine; Fluoxetine; Locomotor activity

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; DOPAMINE; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; ARTICLE; BRAIN LEVEL; DRUG EFFECT; MALE; MOTOR ACTIVITY; PHYSIOLOGY; RAT; RAT STRAIN;

ANIMALS; BRAIN CHEMISTRY; DOPAMINE; FLUOXETINE; HYDROXYINDOLEACETIC ACID; MALE; MOTOR ACTIVITY; RATS; RATS, INBRED STRAINS; SEROTONIN UPTAKE INHIBITORS;

EID: 33750620485     PISSN: 00444677     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Russian source
2. Baldessarini R.J., Marsh E.R., Kula N.S. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions // Brain Res. 1992. V. 579. No 1. P. 152-156.
3. Baldessarini R.J., Tarsy D. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs // Ann. Rev. Neurosci. 1980. V. 3. No 1. P. 23-41.
4. Beasley C.M. Jr., Potvin J.H. Fluoxetine: activating and sedating effects // Int. Clin. Psychopharmacol. 1993. V. 8. No 4. P.271-275.
5. Bymaster F.P., Zhang W., Carter P.A., Shaw J., Chernet E., Phebus L., Wang D.T., Perry K.W. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex // Psychopharmacology. 2002. V. 160. No 4. P. 353-361.
6. Caccia S., Fracassa C., Garattini S., Guiso G., Sarati S. Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain // Neuropharmacology. 1992. V. 31. No 4. P. 343-347.
7. Durand M., Berton O., Aguerre S., Edno L., Combourieu I., Mormede P., Chaouloff F. Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis in SHR and WKY rats // Neuropharmacology. 1999. V. 38. No 6. P. 893-907.
8. Espejo E.F. Selective dopamine depletion within the medial prefrontal cortex induces anxiogenic-like effects in rats placed on the elevated plus maze // Brain Res. 1997. V. 762. No 1-2. P. 281-284.
9. File S.E., Ouagazzal A.-M., Gonzalez L.E., Overstreet D.H. Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function // Pharmacol. Biochem. Behav. 1999. V. 62. No 4. P. 695-701.
10. Fletcher P.J., Korth K.M., Chambers J.W. Selective destruction of brain serotonin neurons by 5.7-dihydroxytryptamine increases responding for a conditioned reward // Psychopharmacology. 1999. V. 147. No 3. P. 291-299.
11. Gardier A.M., Lepoul E., Trouvin J.H., Chanut E., Dessalles M.C., Jacquot C. Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine // Life Sci. 1994. V. 54. No 4. P. PL51-56.
12. Glickstein S.B., Schmauss C. Dopamine receptor functions: lessions from knockout mice // Pharmacol. Ther. 2001. V. 91. No 1. P. 63-83.
13. Gobert A., Rivet J.M., Cistarelli L., Melon C., Millan M.J. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin 1A receptors and blockade of alpha2-adrenergic receptors underlie its actions // Neuroscience. 1999. V. 93. No 4. P. 1251-1262.
14. Harkin A., Shanahan E., Kelly J.P., Connor T.J. Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine // Eur. J. Neurosci. 2003. V. 18. No 4. P. 1021-1027.
15. Hervas I., Vilaro M.T., Romero L., Scorza C., Mengod G., Artigas F. Desensitization of 5-HT 1A autoreceptors by a low chronic fluoxetine dose. Effect of the concurrent administration of WAY-100635 // Neuropsychopharmacology. 2001. V. 24. No 1. P. 11-20.
16. Holmes A., Lachowicz J.E., Sibley D.R. Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes // Neuropharmacology. 2004. V. 47. No 8. P.1117-1134.
17. Ichikawa J., Meltzer H.Y. Effect of antidepressants on striatal and accumbens extracellular dopamine levels // Eur. J. Pharmacol. 1995. V. 281. No 3. P. 255-261.
18. Kreiss D.S., Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo // J. Pharmacol. Exp. Ther. 1995. V. 274. No 2. P. 866-876.
19. Matsumoto M., Togashi H., Mori K., Ueno K., Miyamoto A., Yoshioka M. Characterization of endogenous serotonin mediated regulation of dopamine release in the rat prefrontal cortex // Eur. J. Pharmacol. 1999. V. 383. No 1. P. 39-48.
20. Salgado-Pineda P., Delaveau P., Blin O., Nieoullon A. Dopaminergic contribution to the regulation of emotional perception // Clin. Neuropharmacol. 2005. V. 28. No 5. P. 228-237.
21. Silva M.T., Alves C.R., Santarem E.M. Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze // Braz. J. Med. Biol. Res. 1999. V. 32. No 3. P. 333-339.
22. Wong D.T., Perry K.W., Bymaster P.P. The discovery of fluoxetine hydrochloride (Prozac) // Nat. Rev. Drug Discov. 2005. V. 4. No 9. P.764-774.